Aldeyra Therapeutics Inc (STU:137)
€ 5.158 0.084 (1.66%) Market Cap: 303.87 Mil Enterprise Value: 206.88 Mil PE Ratio: 0 PB Ratio: 3.34 GF Score: 40/100

Aldeyra Therapeutics Inc Provide Results from the Phase 3 Invigorate Clinical Trial Corporate Call Transcript

Apr 27, 2021 / 12:00PM GMT
Release Date Price: €12.3 (+33.70%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Conference Call. (Operator Instructions) I would now like to turn the conference over to your Chief Financial Officer, Joshua Reed. Please go ahead, sir.

Joshua Reed
Aldeyra Therapeutics, Inc. - CFO

Good morning, everyone. With me is Dr. Todd Brady, President and Chief Executive Officer of Aldeyra. This morning, we issued a news release reporting top line results from the Phase III INVIGORATE clinical trial of reproxalap in allergic conjunctivitis. A copy of the news release is available on the Investors & Media section of our website, www.aldeyra.com.

The news release should be read and considered in conjunction with the slides presented and prepared comments made on today's call.

Please turn to Slide 2. This presentation and various remarks, which may be made during this presentation contain forward-looking statements regarding Aldeyra and investigational drug candidate reproxalap.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot